A Phase 1 Study of TRAIL-DR5 antibody DS-8273a Administered in Combination with Nivolumab in Subjects with Unresectable Stage III or Stage IV Melanoma
Brief description of study
If you have been diagnosed with advanced melanoma (a type of skin cancer); you may qualify to participate in a clinical trial that will evaluate the effects of an investigational drug, DS-8273a in combination with nivolumab. The main goal of this phase I study is to determine the level of DS-8273a that remains in the human body at different time points and how safe your body and your disease react to this combination of drugs. Lastly, the trial will evaluate the relationship between biomarkers (proteins) of interest and anti-tumor activity between DS-8273a and nivolumab.
Clinical Study Identifier: s15-00906
ClinicalTrials.gov Identifier: NCTs15-00906
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
